期刊
CELLS
卷 11, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/cells11030413
关键词
lipid metabolism; lung cancer; EGFR; EGFR-TKI resistance
类别
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC) under investigator grant [IG2017-20074]
- AstraZeneca, Milan, Italy
This review explores the role of lipid metabolic reprogramming in lung cancer development and progression, as well as its connection with EGFR signaling. It discusses how increased lipid uptake, synthesis, oxidation, or storage contribute to lung cancer growth, and also summarizes potential therapeutic approaches targeting lipid metabolism for lung cancer treatment.
Lung cancer is the leading cause of cancer deaths worldwide. Most of lung cancer cases are classified as non-small cell lung cancers (NSCLC). EGFR has become an important therapeutic target for the treatment of NSCLC patients, and inhibitors targeting the kinase domain of EGFR are currently used in clinical settings. Recently, an increasing interest has emerged toward understanding the mechanisms and biological consequences associated with lipid reprogramming in cancer. Increased uptake, synthesis, oxidation, or storage of lipids has been demonstrated to contribute to the growth of many types of cancer, including lung cancer. In this review, we provide an overview of metabolism in cancer and then explore in more detail the role of lipid metabolic reprogramming in lung cancer development and progression and in resistance to therapies, emphasizing its connection with EGFR signaling. In addition, we summarize the potential therapeutic approaches targeting lipid metabolism for lung cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据